GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (XPAR:VLA) » Definitions » Shiller PE Ratio

Valneva SE (XPAR:VLA) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Valneva SE Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Valneva SE Shiller PE Ratio Historical Data

The historical data trend for Valneva SE's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Shiller PE Ratio Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.77 - - - -

Valneva SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Valneva SE's Shiller PE Ratio

For the Biotechnology subindustry, Valneva SE's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Valneva SE's Shiller PE Ratio falls into.



Valneva SE Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Valneva SE's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Valneva SE's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.41/119.4700*119.4700
=0.410

Current CPI (Mar. 2024) = 119.4700.

Valneva SE Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.090 100.180 -0.107
201409 -0.050 99.920 -0.060
201412 -0.200 99.860 -0.239
201503 0.140 100.170 0.167
201506 -0.120 100.440 -0.143
201509 -0.070 99.950 -0.084
201512 -0.220 100.040 -0.263
201603 -0.070 100.020 -0.084
201606 -0.460 100.630 -0.546
201609 -0.090 100.340 -0.107
201612 -0.040 100.650 -0.047
201703 -0.020 101.170 -0.024
201706 -0.030 101.320 -0.035
201709 -0.040 101.330 -0.047
201712 -0.050 101.850 -0.059
201803 0.020 102.750 0.023
201806 -0.020 103.370 -0.023
201809 -0.040 103.560 -0.046
201812 0.080 103.470 0.092
201903 0.050 103.890 0.057
201906 -0.080 104.580 -0.091
201909 0.000 104.500 0.000
201912 0.010 104.980 0.011
202003 -0.010 104.590 -0.011
202006 -0.269 104.790 -0.307
202009 -0.410 104.550 -0.469
202012 -0.020 104.960 -0.023
202103 -0.300 105.750 -0.339
202106 -0.610 106.340 -0.685
202109 -1.600 106.810 -1.790
202112 1.760 107.850 1.950
202203 -0.240 110.490 -0.260
202206 -1.340 112.550 -1.422
202209 0.660 112.740 0.699
202212 -0.320 114.160 -0.335
202303 -0.130 116.790 -0.133
202306 -0.120 117.650 -0.122
202309 -0.250 118.260 -0.253
202312 -0.230 118.390 -0.232
202403 0.410 119.470 0.410

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Valneva SE  (XPAR:VLA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Valneva SE Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Valneva SE's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (XPAR:VLA) Business Description

Traded in Other Exchanges
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Valneva SE (XPAR:VLA) Headlines

No Headlines